Skip to main content
. 2014 Jan 7;9(1):e84982. doi: 10.1371/journal.pone.0084982

Figure 1. Effects of gemcitabine on human pancreatic cancer cells.

Figure 1

(A) AsPC-1, BxPC-3, and COLO-357 cells were incubated for 48 h in the absence or presence of varying concentrations of gemcitabine, and MTT assays were performed. Data are the means ± SEM of 3 experiments. *p<0.05; **p<0.01, compared with control. (B) AsPC-1, BxPC-3, and COLO-357 cells were incubated for the indicated times with 100 ng/ml, 10 ng/ml, and 5 ng/ml gemcitabine, respectively, and analyzed by immunoblotting. (C) BxPC-3 cells were incubated for 48 h with 10 ng/ml gemcitabine (G), in the absence or presence of 10 µM SB203580 (SB) or 10 µM SP600125 (SP), and analyzed by immunoblotting.